Stocktoria
PMV Pharmaceuticals, Inc. PMVP
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-09-25
PMV Pharmaceuticals, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $69.9M | $58.5M | $55.9M | $52.0M | $36.5M |
| Operating income | -$86.2M | -$85.4M | -$80.1M | -$77.0M | -$58.3M |
| Income tax | -$2.2M | -$16.1M | $2,000 | -$9,000 | $23,000 |
| Net income | -$77.7M | -$58.7M | -$69.0M | -$73.3M | -$57.8M |
| EPS (diluted) | $-1.48 | $-1.14 | $-1.44 | $-1.61 | $-1.28 |
| Operating cash flow | -$73.6M | -$51.3M | -$55.7M | -$63.8M | -$46.6M |
| Free cash flow | -$73.6M | -$51.9M | -$56.6M | -$71.7M | -$47.9M |
| Cash & equivalents | $38.0M | $40.9M | $37.7M | $108.3M | $172.5M |
| Total assets | $116.6M | $191.3M | $252.2M | $270.3M | $331.6M |
| Total liabilities | $11.8M | $15.2M | $26.5M | $24.3M | $23.0M |
| Shareholders' equity | $104.7M | $176.1M | $225.7M | $246.0M | $308.6M |
Source: SEC EDGAR filings · CIK 0001699382 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.